Faeth Therapeutics, Inc. (FTH) President and CEO Anand Kiran Parikh reported a gift transfer of 100,000 common shares to the AKP Irrevocable Trust on October 30, 2026, for the benefit of his immediate family members. After the transfer, Parikh directly held 717,699 shares, and the trust held 100,000 shares of record. Parikh serves as the trust’s investment advisor with authority to direct its trustee and disclaims beneficial ownership except to the extent of his pecuniary interest.
Faeth Therapeutics, Inc. reported a net loss of $20.398 million for the quarter ended September 30, 2026, compared with $4.569 million a year earlier. Research and development expense was $11.736 million, versus $2.536 million. As of September 30, 2026, cash and cash equivalents were $14.180 million and marketable securities were $160.615 million.
The company said PK/PD analysis informed the PIKTOR dose in its Phase 2 PIK-201 trial, and PIKTOR plus paclitaxel received Fast Track designation for biomarker-selected advanced endometrial cancer. Topline PIK-201 data are anticipated by year-end 2026; initial safety and efficacy data from the PIK-101 breast cancer trial are anticipated in 2027.
Faeth Therapeutics, Inc. reported a $206.6 million net loss for the nine months ended September 30, 2026, versus $16.4 million a year earlier. The loss included $133.0 million of acquired in-process research and development expense from the February acquisition of Legacy Faeth; research and development expense was $38.9 million versus $8.8 million. The acquisition coincided with a private placement generating $200.0 million in gross proceeds. Cash, cash equivalents and marketable securities were $174.8 million at September 30, 2026; the company expects that balance to fund operations for at least 12 months from issuance.
PIKTOR, an oral combination for endometrial and breast cancer, is in a Phase 2 trial for advanced endometrial cancer, with topline data anticipated by year-end 2026; its Phase 1b/2 trial for HR+/HER2- advanced breast cancer began dosing in April 2026, with interim data expected in 2027. In August 2026, the FDA granted Fast Track designation to PIKTOR with paclitaxel for advanced or recurrent endometrial cancer with a PI3K/AKT/mTOR pathway alteration after platinum-based chemotherapy and an immune checkpoint inhibitor. Faeth expects operating losses and negative operating cash flows for the foreseeable future.
Faeth Therapeutics, Inc. director Adam Schayowitz received a grant of stock options covering 25,000 common shares on October 23, 2026, with an exercise price of $17.08 per share and an expiration date of October 22, 2036. The options vest in 36 equal monthly installments over three years, becoming fully vested on October 23, 2029, subject to his continuous service on each vesting date.
Faeth Therapeutics, Inc. (FTH) identifies director Adam Schayowitz as a reporting person in a Form 3.
Faeth Therapeutics, Inc. (FTH) increased its board from six to seven directors and appointed Adam Schayowitz, Ph.D., as a Class III director, effective immediately on October 23, 2026. He will serve until the 2027 annual meeting of stockholders and until a successor is duly elected and qualified, or his earlier death, resignation or removal. Schayowitz has served as Executive Vice President and Head of Research and Development at Zymeworks since April 2026 and previously held oncology development leadership roles at Pfizer Oncology and Tesaro. His appointment includes a cash retainer and an initial option to purchase 25,000 common shares, with an exercise price equal to the closing price of the common stock on the grant date. The board cited his oncology drug development, clinical and regulatory strategy, and commercialization experience in determining his qualifications.
Faeth Therapeutics, Inc. (FTH) reports that its Board of Directors increased in size from five to six members and appointed co‑founder and cancer biologist Karen Vousden, Ph.D. as a Class II director, effective September 11, 2026. Her term runs until the 2029 annual meeting of stockholders, and she was also named to the Board’s Compensation Committee. In connection with her appointment, Dr. Vousden will receive standard non‑employee director cash compensation and an initial equity award under the 2026 Equity Incentive Plan consisting of an option to purchase 25,000 shares of common stock at the closing market price on the grant date, vesting in equal monthly installments over three years and fully vesting upon a Change in Control, subject to continued service.
Faeth Therapeutics, Inc. (FTH) reported that director Karen H. Vousden received a stock option grant for 25,000 shares of common stock on September 11, 2026. The option has an exercise price of $37.44 per share, expires on September 10, 2036, and vests in 36 equal monthly installments through September 11, 2029, contingent on her continued service. No transactions were reported under a Rule 10b5-1 trading plan.
Faeth Therapeutics, Inc. (FTH) reports that director Karen H. Vousden has filed an initial statement of beneficial ownership on Form 3. The filing shows she holds 42,631 shares of the company's Common Stock with direct ownership, and it does not report any recent purchases or sales.
Faeth Therapeutics, Inc., formerly Sensei Biotherapeutics, Inc., reports that Caligan Partners LP and David Johnson have amended their ownership disclosure. They now report beneficial ownership of 629,467 shares of common stock, representing 2.4% of the class, based on 25,840,425 shares outstanding as of July 30, 2026. The shares are held with shared voting and dispositive power through funds and accounts managed by Caligan.
The company changed its corporate name to Faeth Therapeutics, Inc. on June 15, 2026, in connection with its acquisition of Faeth Holdings Therapeutics, Inc. and a concurrent private placement of Series B Non-Voting Convertible Preferred Stock, completed in February 2026. Following stockholder approval on June 10, 2026, these preferred shares automatically converted into common stock on June 15, 2026, and the common stock began trading on the Nasdaq Capital Market under the symbol FTH on June 16, 2026. The amendment states that the reporting persons have ceased to be beneficial owners of more than five percent of the class.